Liver cirrhosis represents end-stage fibrotic liver disease, characterised by irreversible scar tissue replacing functional hepatocytes, portal hypertension, and loss of synthetic function.
Liver cirrhosis represents end-stage fibrotic liver disease, characterised by irreversible scar tissue replacing functional hepatocytes, portal hypertension, and loss of synthetic function. Stem-cell investigations focus on whether placental mesenchymal stem cells can reduce hepatic fibrosis, promote hepatocyte regeneration, and modulate the immunological and inflammatory drivers of progression. MSCs secrete hepatoprotective factors and anti-fibrotic cytokines (TGF-β antagonists, HGF, FGF) that may arrest stellate-cell activation and collagen deposition. With 89 registered trials — the largest cohort among studied conditions — and 7 currently recruiting, the biological rationale targets the fibrotic cascade rather than curative reversal of established cirrhosis. Early clinical data suggest potential for slowing decompensation, improving synthetic function markers, and delaying transplantation.
| التكلفة الموضحة · بلغاريا (الاتحاد الأوروبي) | €3,000–€8,000 |
|---|---|
| نطاق تكاليف السوق العالمي | €19,300–€24,000 (bookinghealth.com) |
| أهم أنواع الخلايا المدروسة | خلايا جذعية وسيطة من غشاء السلى |
| حالة الموافقة | تجريبي |
| التجارب المسجلة (ClinicalTrials.gov) | 89 · 7 recruiting now |
For the clinic's own description, see how Stem Plus describes its Liver Cirrhosis programme ↗.
Cirrhosis trials represent the most mature evidence base among stem-cell-investigated liver diseases. Published studies have documented improvements in liver synthetic function (albumin, prothrombin time), reductions in portal hypertension parameters, and enhanced hepatic blood flow following MSC infusion. Several trials reported reduced variceal bleeding incidence and slower progression to hepatic encephalopathy. However, many studies remain observational and uncontrolled; head-to-head comparisons with standard care (diuretics, beta-blockers, endoscopic banding) are sparse. Disease heterogeneity — varying aetiology (viral hepatitis, alcohol, autoimmune) and cirrhosis stage — limits generalisation of results. Long-term transplant-free survival data are limited; many patients eventually require liver transplantation despite MSC treatment.
Depending on assessment, a Liver Cirrhosis protocol may draw on:
Cirrhosis stem-cell treatment costs typically range €3,500–8,000 per cycle, reflecting the complexity of cell expansion, multiple infusions, and intensive hepatological monitoring required. Systemic intravenous infusion and hepatic artery catheterisation (in selected protocols) add procedural costs. Cell dose is often higher for cirrhosis than joint-specific conditions, increasing manufacturing expense. Hospital-based programmes with on-site cell facilities typically charge less than standalone private clinics. Ancillary costs — imaging, lab testing, gastroenterology evaluation, variceal screening — substantially increase total per-cycle expense. European university hospitals generally offer lower rates than private boutique providers.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Liver Cirrhosis cost-by-country breakdown, or compare the best countries for Liver Cirrhosis →
Before booking, check safety & regulation, the recovery climate, ما إذا كنت قد تكون مرشحاً, and which cell type fits Liver Cirrhosis.
أسئلة تليف الكبد الشاملة → · تفصيل تكاليف تليف الكبد →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: هل أنا مرشح؟ · أي نوع خلايا؟ · Types of clinics & best countries · حاسبة التكاليف
تم المراجعة الطبية بواسطة فريق التحرير StemCellAtlas مع Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) من عيادة الشريك Stem Plus (صوفيا)، وفقاً لـ ISSCR و FDA و EMA. Educational information, not medical advice; figures indicative.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية